Compare Delta Air Lines, Inc. (DAL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Delta Air Lines, Inc. trades at $79.65 (market cap $54.02B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Delta Air Lines, Inc. is far larger — about 25.2× Recursion Pharmaceuticals Inc's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DAL | RXRX | |
|---|---|---|
Market Cap | $54.02B | $2.14B |
Volume | 9,632,845 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $93.66 | $6.79 |
52-Week Low | $55.65 | $2.84 |
Typical Hold Time | 97 Days | 22 Days |
Enterprise Value | $69.34B | $1.66B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters and maintains solid profitability with 5.78% net margin and 20.12% ROE. Recent news highlights competitive pressures from United and American Airlines' customer poaching efforts and Elon Musk's criticism over Delta's Wi-Fi provider choice.
DAL presents a compelling value opportunity with a P/E of 13.62 below industry averages and strong analyst consensus (82% buy ratings) targeting $103.36. However, rising fuel costs, competitive threats to premium customers, and bearish technical indicators create near-term headwinds. The upcoming Q3 earnings report on October 9 will be crucial for validating the company's margin resilience.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
